Received Dec 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 55KB9 | — |
Headache; Nausea; temperature of 101 degree Fahrenheit; Fatigue; This non-serious case was reported by a consumer via call center representative and described the occurrence of headache in a elderly female patient who received Herpes zoster (Shingrix) (batch number 55KB9, expiry date APR-2027) for prophylaxis. On 11-SEP-2025, the patient received Shingrix. In 2025, an unknown time after receiving Shingrix, the patient experienced nausea (Verbatim: Nausea), body temperature increased (Verbatim: temperature of 101 degree Fahrenheit) and fatigue (Verbatim: Fatigue). On an unknown date, the patient experienced headache (Verbatim: Headache). The outcome of the headache, nausea, body temperature increased and fatigue were not resolved. It was unknown if the reporter considered the headache, nausea, body temperature increased and fatigue to be related to Shingrix. It was unknown if the company considered the headache, nausea, body temperature increased and fatigue to be related to Shingrix. Additional Information: GSK Receipt Date-12-DEC-2025 This report was submitted via the online direct entry reporting system. Reporter was patient's husband. After the patient received the Shingrix vaccine, she started to experienced headaches, nausea, fatigue, and temperature of 101 degree Fahrenheit.
Test Name: body temperature; Result Unstructured Data: (Test Result:101,Unit:degree F,Normal Low:,Normal High:)